Surgery after EGFR TKI shows promise in prolonging progression-free survival in metastatic NSCLC

Published Date: 10 Sep 2025

A randomized Phase II trial from National Taiwan University Hospital reports early evidence that resecting the primary thoracic tumor following EGFR tyrosine kinase inhibitor (TKI) therapy may prolong disease control in patients ...

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Interleukin-6 may boost prediction of obesity-related cancers

2.

Immunotherapy after surgery is good for patients with advanced cancer

3.

Blood tests can predict the risk of relapse after a bone marrow transplant in patients with acute myeloid leukemia.

4.

Sevabertinib Approved for First-Line Mutated NSCLC

5.

CAR-T cell therapy for cancer causes 'brain fog,' study shows


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot